Theratechnologies inc.

Theratechnologies inc.

January 17, 2007 10:01 ET

Theratechnologies Comments on Increased Market Activity

MONTREAL, QUEBEC--(CCNMatthews - Jan. 17, 2007) - At the request of Market Surveillance on behalf of the Toronto Stock Exchange, Theratechnologies (TSX:TH) today issued the following statement on recent stock market activity in its stock.

Following the December 19, 2006 announcement of positive Phase 3 data for its lead compound, TH9507 in HIV-associated lipodystrophy, the Company's stock has traded up steadily on increased volumes. Theratechnologies is not aware of any other developments that could be impacting the market for its stock.

About Theratechnologies

Theratechnologies is a Canadian biopharmaceutical company that discovers or acquires innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is TH9507, now in Phase 3 clinical trials for a serious metabolic disorder known as HIV-associated lipodystrophy. The Company also has other promising projects at earlier stages of development.

Contact Information